Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 320 results for falls

  1. AposHealth for knee osteoarthritis (MTG76)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

  2. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  3. Balloon dilation for chronic eustachian tube dysfunction (IPG665)

    Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children. This involves using a balloon filled with saline to widen the eustachian tube.

  4. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  5. Cataracts in adults: management (NG77)

    This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.

  6. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

  7. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

  8. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

  9. Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG753)

    Evidence-based recommendations on endoluminal gastroplication for gastro-oesophageal reflux disease. This involves an endoscopic fastening device being inserted through the mouth and into the stomach, along with an endoscope for constant visualisation. The device is used to attach the fundus to the anterior and left lateral wall of the distal oesophagus slightly above the oesophagogastric junction.

  10. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  11. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

  12. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

  13. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

  14. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

    Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

  15. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.